The TGFβ/type I IFN interference highlighted in this study is likely to matter not only for STING agonists under active development, but also for chemotherapeutic agents like anthracyclins, for which tumor regression has been associated with a type I IFN signature50. This evidence concerns the gene TGFB1 and neoplasm.